Osteoporos Sarcopenia.  2020 Jun;6(2):39-52. 10.1016/j.afos.2020.05.006.

Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal

Affiliations
  • 1Division of Pharmacology, Department of Pharmaceutical Medicine, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
  • 2Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
  • 3Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth, Pune, India
  • 4Department of Medicine, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi, India

Abstract

This paper systematically and critically reviewed all published economic evaluations of drugs for the treatment postmenopausal osteoporosis. A systematic search was conducted using relevant databases for economic evaluations to include all relevant English articles published between January 2008 to January 2020. After extracting the key study characteristics, methods and outcomes, we evaluated each article using the Quality of Health Economic Studies (QHES) and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) instruments. A total of 49 studies met the inclusion criteria. Majority of studies were funded by the industry and reported favorable cost-effectiveness. Based on the QHES total scores, studies (n ¼ 35) were found to be industry-funded with higher QHES mean 82.44 ± 8.69 as compared with nonindustry funding studies (n ¼ 11) with mean 72.22 ± 17.67. The overall mean QHES scores were found to be higher 79.06 ± 11.84, representing high quality (75e100) compared to CHEERS scores (%) 75.03 ± 11.21. The statistical pairwise comparison between CHEERS mean (75.03 ± 11.21) and QHES mean (79.06 ± 11.84) were not statistically significant (P ¼ 0.10) whereas, QHES score showed higher means as compared to CHEERS. This study suggests the overall quality of the published literatures was relatively few high-quality health economic evaluation demonstrating the cost-effectiveness of drugs for postmenopausal osteoporosis, and the majority of the literature highlights that methodological shortcoming.

Keyword

Health economics; Cost-effectiveness analysis; Postmenopausal osteoporosis; Quality appraisal; Consolidated health economic evaluation; reporting standards; Quality of health economic studies
Full Text Links
  • OS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr